"Gene Symbol","Nominations","Year First Nominated","Nominating Teams","Cohort Study","Program","Input Data","Pharos Class","Small Molecule Druggability","Safety Rating","Antibody Modality"
"MSN","5","2018","Chang Lab, Emory, Emory-Sage-SGC, MSSM - Zhang Lab","ACT, Banner, BLSA, Kronos, MSBB, ROSMAP","AMP-AD, Community, TREAT-AD","Genetics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PLEC","5","2018","Chang Lab, Columbia-Rush, Emory, Emory-Sage-SGC, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB, ROSMAP","AMP-AD, Community, TREAT-AD","Clinical, Genetics, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PRDX1","5","2018","Chang Lab, Columbia-Rush, Emory, Emory-Sage-SGC, MSSM - Zhang Lab","ACT, Banner, BLSA, Kronos, MSBB, ROSMAP","AMP-AD, Community, TREAT-AD","Clinical, Genetics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"APOE","4","2018","ASU, Duke, Mayo-UFL-ISB, MSSM - Roussos Lab","APP Mice, HBI_scRNAseq, VirusResilience","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CLU","4","2018","Columbia-Rush, Duke, Mayo-UFL-ISB, MSSM - Roussos Lab","ADNI, APP Mice, FreshMicro, ROSMAP","AMP-AD","Clinical, Genetics, Metabolomics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"INPP5D","4","2018","Duke, IUSM-Purdue, Mayo-UFL-ISB, MSSM - Zhang Lab","ABA, ADNI, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","Genetics, Metabolomics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"PRDX6","4","2018","Chang Lab, Emory, Emory-Sage-SGC, MSSM - Zhang Lab","ACT, Banner, BLSA, Kronos, MSBB, Rush","AMP-AD, Community, TREAT-AD","Genetics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"RPH3A","4","2018","Chang Lab, Columbia-Rush, Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB, ROSMAP","AMP-AD, Community","Clinical, Genetics, Protein","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"VGF","4","2018","Columbia-Rush, Emory, Mayo-UFL-ISB, MSSM - Zhang Lab","ACT, Banner, BLSA, Mayo, MSBB, ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"ACE","3","2018","Duke, Emory","ADNI, Banner, https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2, ROSMAP","AMP-AD","Genetics, Metabolomics, Protein","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"BIN1","3","2018","ASU, Duke, Mayo-UFL-ISB","ADNI, Mayo, VirusResilience","AMP-AD","Genetics, Metabolomics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"CTSH","3","2020","Emory, Emory-Sage-SGC","Banner, https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2, ROSMAP","AMP-AD, TREAT-AD","Genetics, Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"DBI","3","2018","Columbia-Rush, Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB, ROSMAP","AMP-AD","Clinical, Genetics, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"DNM1","3","2018","Chang Lab, Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, Kronos, Mayo, MSBB, ROSMAP","AMP-AD, Community","Genetics, Protein, RNA","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"ERBB3","3","2018","ASU, Columbia-Rush, Mayo-UFL-ISB","Mayo, ROSMAP, VirusResilience","AMP-AD","Clinical, Genetics, Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"GSN","3","2018","Chang Lab, Columbia-Rush, MSSM - Zhang Lab","Kronos, MSBB, ROSMAP, Rush","AMP-AD, Community","Clinical, Genetics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"HTRA1","3","2018","Emory, Mayo-UFL-ISB, MSSM - Roussos Lab","APP Mice, Banner, Emory, HBI_scRNAseq, MSBB, ROSMAP","AMP-AD","Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"MDK","3","2018","Emory, Emory-Sage-SGC, Mayo-UFL-ISB","Banner, Emory, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"NDUFA10","3","2018","Chang Lab, Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB","AMP-AD, Community","Genetics, Protein","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"NRN1","3","2018","Columbia-Rush, MSSM - Zhang Lab","MSBB, ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PDHB","3","2018","Chang Lab, Columbia-Rush, Emory","ACT, Banner, BLSA, MSBB, ROSMAP","AMP-AD, Community","Clinical, Genetics, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"RABEP1","3","2018","Duke, Emory-Sage-SGC, MSSM - Roussos Lab","ADNI, Banner, FreshMicro, ROSMAP","AMP-AD, TREAT-AD","Genetics, Metabolomics, Protein, RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"RUFY3","3","2018","Duke, Emory, MSSM - Roussos Lab","ACT, ADNI, Banner, BLSA, HBI_scRNAseq","AMP-AD","Genetics, Metabolomics, Protein, RNA","Tdark","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"SEPTIN5","3","2018","ASU, Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB, VirusResilience","AMP-AD","Protein, RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"SFRP1","3","2018","Emory, Emory-Sage-SGC, Mayo-UFL-ISB","APP Mice, Banner, Emory, MSBB, ROSMAP","AMP-AD, TREAT-AD","Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"SLC25A11","3","2018","Chang Lab, Columbia-Rush, Emory","ACT, Banner, BLSA, MSBB, ROSMAP","AMP-AD, Community","Clinical, Genetics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SNX32","3","2020","Emory, Emory-Sage-SGC","Banner, https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2, ROSMAP","AMP-AD, TREAT-AD","Genetics, Protein","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"SYK","3","2018","Emory-Sage-SGC, IUSM-Purdue, MSSM - Zhang Lab","ABA, Banner, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","Genetics, Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SYNGAP1","3","2018","Chang Lab, Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB","AMP-AD, Community","Genetics, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SYT1","3","2018","Chang Lab, Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, Kronos, Mayo, MSBB, ROSMAP, Rush","AMP-AD, Community","Genetics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TYROBP","3","2018","IUSM-Purdue, Mayo-UFL-ISB, MSSM - Zhang Lab","ABA, GSE33000, GSE44772, GSE48350, GSE5281, HBTRC, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","Genetics, RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ABI3","2","2018","IUSM-Purdue, Mayo-UFL-ISB","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"ADAMTS4","2","2018","ASU, Duke","ADNI, VirusResilience","AMP-AD","Genetics, Metabolomics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ANKS1B","2","2018","Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"AP2B1","2","2018","Chang Lab, Emory","ACT, Banner, BLSA, MSBB, Rush","AMP-AD, Community","Genetics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"APOC1","2","2018","Duke, MSSM - Roussos Lab","ADNI, FreshMicro","AMP-AD","Genetics, Metabolomics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"ATP1B1","2","2018","Chang Lab, Columbia-Rush","Kronos, Mayo, MSBB, ROSMAP, Rush","AMP-AD, Community","Clinical, Genetics, Protein, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ATP2A2","2","2018","Columbia-Rush, Emory","ACT, Banner, BLSA, ROSMAP","AMP-AD","Clinical, Protein","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ATP2B1","2","2018","Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB","AMP-AD","Genetics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ATP6V1A","2","2018","Chang Lab, MSSM - Zhang Lab","Kronos, Mayo, MSBB, ROSMAP, Rush","AMP-AD, Community","Genetics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"C1QTNF4","2","2018","Columbia-Rush, Mayo-UFL-ISB","Mayo, ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"C4A","2","2018","Columbia-Rush, Emory-Sage-SGC","ACT, Banner, BLSA, ROSMAP","AMP-AD, TREAT-AD","Clinical, Genetics, Protein, RNA","No value","No value","No value","No value"
"CACNB4","2","2018","MSSM - Roussos Lab, MSSM - Zhang Lab","HBI_scRNAseq, MSBB","AMP-AD","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CAPN2","2","2018","Emory, Emory-Sage-SGC","ACT, Banner, BLSA","AMP-AD, TREAT-AD","Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"CD44","2","2018","Emory, Emory-Sage-SGC","ACT, Banner, BLSA","AMP-AD, TREAT-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CDK18","2","2019","Chang Lab, Mayo-UFL-ISB","GSE197305, Kronos, Mayo, MC-CAA, ROSMAP, Rush","AMP-AD, Community","Genetics, Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"CHADL","2","2018","Columbia-Rush, Emory","ROSMAP, syn20933797, syn52525880","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CIRBP","2","2019","Chang Lab, MSSM - Roussos Lab","HBI_scRNAseq, Kronos, Mayo, ROSMAP","AMP-AD, Community","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"CLIC1","2","2018","Chang Lab, MSSM - Zhang Lab","Kronos, Mayo, MSBB, ROSMAP, Rush","AMP-AD, Community","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"COL25A1","2","2018","Emory, Mayo-UFL-ISB","APP Mice, Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","2: Component of the extracellular matrix (ECM). Highly accessible to antibody-based therapies, but potentially less so than secreted proteins."
"CPLX1","2","2018","Columbia-Rush, Emory","https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2, ROSMAP","AMP-AD","Clinical, Genetics, Protein","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"CS","2","2018","Chang Lab, Columbia-Rush","MSBB, ROSMAP","AMP-AD, Community","Clinical, Genetics, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CSF1R","2","2018","IUSM-Purdue, Mayo-UFL-ISB","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CSMD1","2","2018","Duke, MSSM - Zhang Lab","ADNI, MSBB","AMP-AD","Genetics, Metabolomics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CYBA","2","2019","Chang Lab, IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Kronos, Mayo, MSBB, ROSMAP, Rush","Community, TREAT-AD","Genetics, RNA","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DDAH2","2","2018","Columbia-Rush, Emory","ACT, Banner, BLSA, ROSMAP","AMP-AD","Clinical, Protein","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DLGAP2","2","2021","JAX-VUMC-UW Resilience, MSSM - Zhang Lab","Diversity outbred mice, MSBB, ROSMAP","AMP-AD, Resilience-AD","Clinical, Genetics, Protein, RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"DOC2A","2","2020","Emory","Banner, https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2, ROSMAP","AMP-AD","Genetics, Protein","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"DOCK2","2","2018","IUSM-Purdue, MSSM - Zhang Lab","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DPP6","2","2018","Chang Lab, Emory","ACT, Banner, BLSA, Mayo, MSBB","AMP-AD, Community","Genetics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DYNC1I1","2","2018","Chang Lab, MSSM - Zhang Lab","Kronos, Mayo, MSBB, ROSMAP, Rush","AMP-AD, Community","Genetics, RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"EPB41L3","2","2018","Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"EPHA1","2","2018","Duke, Mayo-UFL-ISB","ADNI, Mayo","AMP-AD","Genetics, Metabolomics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"EPHX2","2","2022","Duke, Emory-Sage-SGC","Banner, ROSMAP","AMP-AD, TREAT-AD","Genetics, Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"FCER1G","2","2018","Emory-Sage-SGC, Mayo-UFL-ISB","Banner, Mayo, ROSMAP","AMP-AD, TREAT-AD","Genetics, Protein, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"FIBP","2","2019","Chang Lab, MSSM - Roussos Lab","FreshMicro, Kronos, Mayo, ROSMAP","AMP-AD, Community","Genetics, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"FOXO1","2","2018","Duke, MSSM - Roussos Lab","ADNI, HBI_scRNAseq","AMP-AD","Genetics, Metabolomics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"GABRA2","2","2023","ASU, Duke","VirusResilience","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"GFAP","2","2018","Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB","AMP-AD","Genetics, Protein","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"GIMAP8","2","2022","IUSM-Purdue, MSSM - Roussos Lab","ABA, GSE33000, GSE44772, GSE48350, GSE5281, HBI_scRNAseq, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"GMPR","2","2018","Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"GPNMB","2","2020","Emory, Emory-Sage-SGC","Banner, Emory, MSBB, ROSMAP","AMP-AD, TREAT-AD","Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"GRIA2","2","2018","Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB","AMP-AD","Genetics, Protein, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"HLA-DRA","2","2019","Chang Lab, IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Kronos, Mayo, MSBB, ROSMAP, Rush","Community, TREAT-AD","Genetics, RNA","No value","No value","No value","No value"
"HNRNPM","2","2018","Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"HOMER1","2","2018","Chang Lab, Emory","ACT, Banner, BLSA, Kronos, Mayo, ROSMAP, Rush","AMP-AD, Community","Genetics, Protein, RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"HSPB1","2","2018","Columbia-Rush, Emory","ACT, Banner, BLSA, ROSMAP","AMP-AD","Clinical, Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"IGF1","2","2018","Mayo-UFL-ISB, MSSM - Roussos Lab","HBI_scRNAseq, Mayo","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"IL10RA","2","2018","IUSM-Purdue, Mayo-UFL-ISB","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ITGAM","2","2022","IUSM-Purdue, MSSM - Roussos Lab","ABA, GSE33000, GSE44772, GSE48350, GSE5281, HBI_scRNAseq, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ITGB2","2","2020","IUSM-Purdue, MSSM - Zhang Lab","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","Genetics, Protein, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"KALRN","2","2018","Columbia-Rush, MSSM - Zhang Lab","MSBB, ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"LACTB","2","2020","Emory","Banner, https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2, ROSMAP","AMP-AD","Genetics, Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"LAG3","2","2018","JAX-VUMC-UW Resilience, Mayo-UFL-ISB","AD-BXD mice, Mayo","AMP-AD, Resilience-AD","Behavior, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"LAIR1","2","2022","Duke, IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","No value","No value","No value","No value"
"LAPTM5","2","2019","Chang Lab, JAX-VUMC-UW Resilience","AD-BXD mice, Kronos, Mayo, ROSMAP","Community, Resilience-AD","Behavior, Genetics, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"LCP1","2","2022","IUSM-Purdue, MSSM - Zhang Lab","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"LMNA","2","2018","Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB","AMP-AD","Protein","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"LYVE1","2","2018","Mayo-UFL-ISB, MSSM - Roussos Lab","HBI_scRNAseq, Mayo","AMP-AD","RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"MEF2C","2","2018","Duke, MSSM - Zhang Lab","ADNI, MSBB","AMP-AD","Genetics, Metabolomics, RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"MOBP","2","2018","ASU, Mayo-UFL-ISB","Mayo, VirusResilience","AMP-AD","RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"MRC1","2","2023","ASU, MSSM - Roussos Lab","HBI_scRNAseq, VirusResilience","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"MRPL37","2","2018","Columbia-Rush, Duke","ROSMAP","AMP-AD","Clinical, Genetics, Metabolomics, Phenomics, Protein, RNA","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"MS4A4A","2","2018","IUSM-Purdue, Mayo-UFL-ISB","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","Genetics, RNA","Tbio","10: Potentially small molecule druggable by family (low activity ligand): is a member of a gene family which has a protein member with a ligand which does not meet TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"MS4A6A","2","2018","IUSM-Purdue, Mayo-UFL-ISB","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","RNA","Tbio","10: Potentially small molecule druggable by family (low activity ligand): is a member of a gene family which has a protein member with a ligand which does not meet TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"NDUFS1","2","2018","Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB","AMP-AD","Protein","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","6: Protein located in intracellular compartment. "
"NDUFS2","2","2018","Emory, Emory-Sage-SGC","ACT, Banner, BLSA, Emory, MSBB, ROSMAP","AMP-AD, TREAT-AD","Protein, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"NDUFS3","2","2023","Mayo, MSSM - Zhang Lab","Mayo, MSBB, ROSMAP","AMP-AD, Resilience-AD","Genetics, Protein, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"NDUFV1","2","2018","Emory, Mayo","ACT, Banner, BLSA, Mayo, MSBB, ROSMAP","AMP-AD, Resilience-AD","Genetics, Protein, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"NLRC5","2","2018","Duke, MSSM - Zhang Lab","ADNI, MSBB","AMP-AD","Genetics, Metabolomics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"NNT","2","2018","Columbia-Rush, Emory","ACT, Banner, BLSA, ROSMAP","AMP-AD","Clinical, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"NONO","2","2018","Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"NRXN3","2","2018","ASU, Duke","ADNI, VirusResilience","AMP-AD","Genetics, Metabolomics, RNA","No value","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"OLFM1","2","2018","Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"OLFM3","2","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, Protein, RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","1: Secreted protein. Highly accessible to antibody-based therapies."
"PADI2","2","2018","Emory, MSSM - Roussos Lab","ACT, Banner, BLSA, HBI_scRNAseq","AMP-AD","Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"PAFAH1B3","2","2018","Columbia-Rush, Emory","ACT, Banner, BLSA, ROSMAP","AMP-AD","Clinical, Protein","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"PAK1","2","2018","Chang Lab, MSSM - Zhang Lab","Kronos, MSBB, ROSMAP","AMP-AD, Community","Genetics, Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PDHA1","2","2018","Columbia-Rush, MSSM - Zhang Lab","MSBB, ROSMAP","AMP-AD","Clinical, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","1: Secreted protein. Highly accessible to antibody-based therapies."
"PGLS","2","2018","Columbia-Rush, Emory","ACT, Banner, BLSA, ROSMAP","AMP-AD","Clinical, Protein","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"PICALM","2","2018","Duke, MSSM - Roussos Lab","ADNI, FreshMicro","AMP-AD","Genetics, Metabolomics, RNA","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PLCB1","2","2018","Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PLCG2","2","2018","IUSM-Purdue, Mayo-UFL-ISB","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"PLXNB1","2","2018","Columbia-Rush, MSSM - Zhang Lab","MSBB, ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PREX1","2","2018","Chang Lab, Columbia-Rush","ROSMAP","AMP-AD, Community","Clinical, Genetics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"PTN","2","2018","Emory, Mayo-UFL-ISB","Banner, Emory, Mayo, MSBB, ROSMAP","AMP-AD","Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"PTPN6","2","2022","IUSM-Purdue, MSSM - Zhang Lab","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","Genetics, Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","6: Protein located in intracellular compartment. "
"PTPRC","2","2020","IUSM-Purdue, MSSM - Zhang Lab","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","Genetics, Protein, RNA","No value","No value","No value","No value"
"RAB27B","2","2018","Emory, MSSM - Zhang Lab","Banner, MSBB, ROSMAP","AMP-AD","Genetics, Protein, RNA","Tbio","6: Probably small molecule druggable by homology: >=40% homologous to a  protein with a small molecule ligand identified from ChEMBL data, but the ligand does not meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"RAB3A","2","2018","Columbia-Rush, Emory","ACT, Banner, BLSA, ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","6: Probably small molecule druggable by homology: >=40% homologous to a  protein with a small molecule ligand identified from ChEMBL data, but the ligand does not meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"RTF2","2","2020","Emory","Banner, https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2, ROSMAP","AMP-AD","Genetics, Protein","Tdark","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"SCARA3","2","2018","ASU, Duke","ADNI, VirusResilience","AMP-AD","Genetics, Metabolomics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SDC4","2","2020","Emory, Emory-Sage-SGC","Banner, Emory, MSBB, ROSMAP","AMP-AD, TREAT-AD","Protein","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SIPA1","2","2018","IUSM-Purdue, MSSM - Zhang Lab","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLIT2","2","2018","Duke, Emory","ADNI, Banner, Emory, MSBB, ROSMAP","AMP-AD","Genetics, Metabolomics, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"SLIT3","2","2018","Duke, Emory","ADNI, syn20933797, syn52525880","AMP-AD","Genetics, Metabolomics, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"SMOC1","2","2020","Emory, Emory-Sage-SGC","Banner, Emory, MSBB, ROSMAP","AMP-AD, TREAT-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"SNAP91","2","2018","Chang Lab, MSSM - Zhang Lab","Kronos, Mayo, MSBB, ROSMAP","AMP-AD, Community","Genetics, RNA","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"SPON1","2","2020","Emory, MSSM - Roussos Lab","Banner, Emory, FreshMicro, MSBB, ROSMAP","AMP-AD","Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"STAT3","2","2018","Mayo-UFL-ISB, MSSM - Zhang Lab","Mayo, MSBB","AMP-AD","Genetics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"STX1A","2","2018","Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB","AMP-AD","Protein","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"STX4","2","2020","Emory, Emory-Sage-SGC","Banner, ROSMAP","AMP-AD, TREAT-AD","Genetics, Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"STX6","2","2020","Emory","Banner, https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2, ROSMAP","AMP-AD","Genetics, Protein","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SV2B","2","2018","Emory, MSSM - Zhang Lab","ACT, Banner, BLSA, MSBB","AMP-AD","Genetics, Protein, RNA","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SYT7","2","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TAGLN3","2","2018","Columbia-Rush, MSSM - Zhang Lab","MSBB, ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"TGFBR2","2","2018","Mayo-UFL-ISB, MSSM - Zhang Lab","Mayo, MSBB","AMP-AD","Genetics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TLN1","2","2018","Chang Lab, MSSM - Zhang Lab","Mayo, MSBB, ROSMAP","AMP-AD, Community","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"TLR2","2","2018","IUSM-Purdue, Mayo-UFL-ISB","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"TNFRSF1A","2","2018","Chang Lab, MSSM - Zhang Lab","Kronos, Mayo, MSBB, ROSMAP, Rush","AMP-AD, Community","Genetics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"TREM2","2","2018","IUSM-Purdue, Mayo-UFL-ISB","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"VSNL1","2","2018","ASU, MSSM - Zhang Lab","MSBB, VirusResilience","AMP-AD","Genetics, RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"WDFY4","2","2018","IUSM-Purdue, MSSM - Zhang Lab","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","AMP-AD, TREAT-AD","Genetics, RNA","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"WDR1","2","2019","Chang Lab, MSSM - Zhang Lab","MSBB","AMP-AD, Community","Genetics, Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"AADAT","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ABCA7","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","10: Potentially small molecule druggable by family (low activity ligand): is a member of a gene family which has a protein member with a ligand which does not meet TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ABCA8","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ABLIM2","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"ACO2","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ACOT1","1","2023","Emory","https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2","AMP-AD","Genetics, Protein","Tdark","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ACOT11","1","2023","MSSM - Roussos Lab","FreshMicro","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"ACSL1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ACTN1","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ACTN2","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ADAM10","1","2023","Emory","https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2","AMP-AD","Genetics, Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"ADAM9","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","No value","No value","No value","No value"
"ADAMTS1","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"ADAMTS17","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"ADD3","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"AGT","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"AHCYL1","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"AHNAK","1","2020","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"AIFM1","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"AK1","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"AK4","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"AKR1D1","1","2020","ASU","ROSMAP","AMP-AD","Genetics, Protein, RNA","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","6: Protein located in intracellular compartment. "
"AKT1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ALCAM","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ALDH1A2","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ALDH4A1","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ALK","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ANK3","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"ANKRD31","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"ANO6","1","2019","Chang Lab","Mayo","Community","Genetics, RNA","Tbio","9: Potentially small molecule druggable by family (active ligand): is a member of a gene family which has a member with an small molecule ligand identified from ChEMBL data, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ANP32B","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"ANXA1","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ANXA2","1","2020","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ANXA5","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","6: Protein located in intracellular compartment. "
"AP1B1","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"AP2A1","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"AP2M1","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"AP3B2","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"AP3D1","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"APOD","1","2018","Mayo-UFL-ISB","APP Mice","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","1: Secreted protein. Highly accessible to antibody-based therapies."
"ARHGAP17","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"ARHGAP20","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"ARHGAP26","1","2019","Chang Lab","MSBB, ROSMAP","Community","Genetics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ARHGAP30","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"ARHGDIB","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","6: Probably small molecule druggable by homology: >=40% homologous to a  protein with a small molecule ligand identified from ChEMBL data, but the ligand does not meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"ARHGEF2","1","2022","Emory-Sage-SGC","","TREAT-AD","Pathway Modeling, Risk Scores","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"ARID5B","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ARPC1B","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"ASAH1","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"ASAP1","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ASPM","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ASTN1","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ATCAY","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ATL3","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ATP1A3","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ATP1B3","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ATP2B2","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ATP5PO","1","2019","Chang Lab","MSBB, Rush","Community","Genetics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"ATP6V0A1","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ATP6V0D1","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ATP6V1B2","1","2019","Chang Lab","MSBB, ROSMAP, Rush","Community","Genetics, Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"ATP6V1E1","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"ATP6V1E2","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"ATP6V1H","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"BAG4","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"BAIAP2","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"BBX","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"BCAM","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"BCAS1","1","2019","Chang Lab","MSBB","Community","Genetics, Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"BCKDK","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"BCL2","1","2019","Chang Lab","ROSMAP","Community","Genetics, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"BDH2","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"BDNF","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"BLOC1S1","1","2020","ASU","ROSMAP","AMP-AD","Genetics, Protein, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"BMPER","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"BRINP2","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tdark","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"BSCL2","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"BSN","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"BTBD8","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","No value","No value","No value","No value"
"BTK","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"C1QA","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"C1QB","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"C2orf83","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tdark","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"C3","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"C3AR1","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CACNA1A","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CADM1","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CADM2","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CADPS","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CALD1","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CAMKK2","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CARHSP1","1","2020","Emory","Banner, ROSMAP","AMP-AD","Genetics, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"CASS4","1","2023","MSSM - Roussos Lab","FreshMicro","AMP-AD","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"CBL","1","2019","Chang Lab","ROSMAP","Community","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"CCDC6","1","2023","Emory","https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2","AMP-AD","Genetics, Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"CCDC89","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tdark","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"CCT6B","1","2019","Chang Lab","Mayo","Community","Genetics, RNA","Tdark","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"CD22","1","2023","Mayo-UFL-ISB","GSE197305, Mayo, MC-CAA, ROSMAP","AMP-AD","Protein, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CD2AP","1","2023","Emory","https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2","AMP-AD","Genetics, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"CD300A","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CD33","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CD47","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CD74","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CD81","1","2023","MSSM - Roussos Lab","FreshMicro","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CD86","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CDC42SE2","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"CDCA7","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"CDCP1","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CDH22","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CDH23","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CDK19","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"CDYL","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CECR2","1","2023","MSSM - Roussos Lab","FreshMicro","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"CELF1","1","2020","ASU","ROSMAP","AMP-AD","Genetics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"CEP170B","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tdark","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"CERCAM","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tdark","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CERS4","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CERS6","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CETP","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CFH","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CFI","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CHCHD3","1","2019","Chang Lab","MSBB","Community","Genetics, Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"CHST1","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CHST11","1","2019","Chang Lab","ROSMAP","Community","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CHSY3","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CISD1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CLEC3B","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CLTCL1","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"CNKSR2","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CNN3","1","2022","Emory-Sage-SGC","ACT, Banner, BLSA","TREAT-AD","Protein, RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"CNP","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"CNTNAP2","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","No value","No value","No value","No value"
"CNTNAP5","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tdark","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"COL11A1","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Clinical, Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"COL18A1","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"COL1A2","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"COL4A4","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"COL5A1","1","2023","Emory","syn20933797, syn52525880","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CORO1C","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"COTL1","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"COX4I1","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"COX5B","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"COX6B1","1","2019","Chang Lab","Kronos, MSBB","Community","Genetics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","6: Protein located in intracellular compartment. "
"CR1","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CRH","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CRHR1","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","No value","No value","No value","No value"
"CSF1","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CSF3R","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CSRP1","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"CTHRC1","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CTLA4","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CTSS","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CX3CL1","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CX3CR1","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CXCL10","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","1: Secreted protein. Highly accessible to antibody-based therapies."
"CYBB","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CYFIP2","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CYP19A1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CYP27A1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CYP3A43","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"CYTL1","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"DAAM1","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DAAM2","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DAG1","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"DAGLA","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DAP3","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DAXX","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"DBT","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"DCAF12","1","2019","Chang Lab","Mayo, ROSMAP","Community","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"DCHS2","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DCLK1","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DCLK2","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DCN","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"DCTN1","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"DDB1","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DDO","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DDR2","1","2023","Mayo-UFL-ISB","Mayo, MC-BrAD, TAUAPPms","AMP-AD","Genetics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"DDX1","1","2022","Emory-Sage-SGC","","TREAT-AD","Pathway Modeling, Risk Scores","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"DENND1B","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DESI1","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tdark","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"DHCR24","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DHRS11","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"DHTKD1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"DHX58","1","2022","Emory-Sage-SGC","","TREAT-AD","Pathway Modeling, Risk Scores","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"DIRAS1","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"DISC1","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"DLD","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"DLG2","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","6: Probably small molecule druggable by homology: >=40% homologous to a  protein with a small molecule ligand identified from ChEMBL data, but the ligand does not meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DLG4","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","1: Secreted protein. Highly accessible to antibody-based therapies."
"DLGAP1","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"DMXL2","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DNAJC6","1","2019","Chang Lab","MSBB, ROSMAP","Community","Genetics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DND1","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"DNM1L","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"DNM2","1","2019","Chang Lab","MSBB","Community","Genetics, Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"DNM3","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"DOCK1","1","2019","Chang Lab","ROSMAP","Community","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"DOCK3","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"DOCK4","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DOCK7","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DOCK8","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DPP10","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DPY30","1","2018","Mayo-UFL-ISB","APP Mice","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"DPYD","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"DPYS","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"DPYSL3","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"DTNA","1","2020","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"DTX3L","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"DYNC2LI1","1","2019","Chang Lab","Kronos, Mayo, ROSMAP, Rush","Community","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"ECE1","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"EDA","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"EDAR","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"EFNA1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"EFNA5","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ELAVL2","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","6: Probably small molecule druggable by homology: >=40% homologous to a  protein with a small molecule ligand identified from ChEMBL data, but the ligand does not meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"ELAVL4","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","6: Probably small molecule druggable by homology: >=40% homologous to a  protein with a small molecule ligand identified from ChEMBL data, but the ligand does not meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"ELL2","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"ELOVL2","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"EN2","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"ENC1","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"ENO1","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ENO3","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"ENOSF1","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"EPHA1-AS1","1","2023","MSSM - Roussos Lab","FreshMicro","AMP-AD","Genetics, RNA","No value","No value","No value","No value"
"EPHA5","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"EPHX1","1","2023","Duke","","AMP-AD","Genetics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ERBB4","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ERBIN","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"ERC2","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"ESRRG","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"ETFA","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"EXOC3L2","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"EYA4","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"EZR","1","2020","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"FA2H","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"FAAH","1","2023","Duke","","AMP-AD","Genetics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"FADS1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"FADS2","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"FADS3","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"FAHD2CP","1","2019","Chang Lab","Mayo","Community","Genetics, RNA","No value","No value","No value","No value"
"FAM107A","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","6: Protein located in intracellular compartment. "
"FAM111A","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"FAM163A","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tdark","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"FAM83E","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tdark","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"FAN1","1","2019","Chang Lab","Mayo, ROSMAP","Community","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"FARSA","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"FBXL16","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"FBXL7","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"FBXO40","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"FBXW7","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"FCGR1A","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"FCGR2A","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"FERMT3","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"FGF1","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"FGF12","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"FGF14","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"FGF2","1","2021","JAX-VUMC-UW Resilience","AD-BXD mice","Resilience-AD","Behavior, Genetics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"FKBP5","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"FLI1","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","6: Probably small molecule druggable by homology: >=40% homologous to a  protein with a small molecule ligand identified from ChEMBL data, but the ligand does not meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"FLNC","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"FLT1","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"FOXE1","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"FPR1","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"FRAT2","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tdark","13: Unknown: There is no information on ligands or structure in any of the categories above. ","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","6: Protein located in intracellular compartment. "
"FRMD3","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"FRMPD4","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"FRZB","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tbio","9: Potentially small molecule druggable by family (active ligand): is a member of a gene family which has a member with an small molecule ligand identified from ChEMBL data, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"FSCN3","1","2019","Chang Lab","Mayo, ROSMAP","Community","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"G3BP2","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"GAB1","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"GABARAPL1","1","2019","Chang Lab","Kronos, ROSMAP","Community","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"GABRA1","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"GABRA4","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"GABRB2","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"GABRG2","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"GAD1","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","6: Probably small molecule druggable by homology: >=40% homologous to a  protein with a small molecule ligand identified from ChEMBL data, but the ligand does not meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"GALNT2","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"GAPDH","1","2019","Chang Lab","Kronos, MSBB, Rush","Community","Genetics, Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"GAS7","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"GBP1","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"GBP2","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"GBP3","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"GCDH","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"GCKR","1","2020","ASU","ROSMAP","AMP-AD","Genetics, Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"GDA","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","6: Protein located in intracellular compartment. "
"GDAP1","1","2019","Chang Lab","Mayo, ROSMAP, Rush","Community","Genetics, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"GDF10","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"GDNF","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"GGTA1","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","No value","No value","No value","No value"
"GIMAP4","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"GIMAP6","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"GJA1","1","2018","MSSM - Zhang Lab","HBTRC","AMP-AD","Genetics, RNA","Tbio","6: Probably small molecule druggable by homology: >=40% homologous to a  protein with a small molecule ligand identified from ChEMBL data, but the ligand does not meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"GLDN","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","2: Component of the extracellular matrix (ECM). Highly accessible to antibody-based therapies, but potentially less so than secreted proteins."
"GMNC","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"GNB5","1","2019","Chang Lab","MSBB","Community","Genetics, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"GPC2","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"GPC5","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"GPC6","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"GPI","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","No value","No value","No value","No value"
"GPM6B","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"GPR37","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"GPR84","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"GPSM3","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","No value","No value","No value","No value"
"GRAMD2B","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"GRAMD4","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"GRIA3","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"GRIN2A","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"GRIN2B","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"GSTK1","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"GUCY1A1","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","6: Protein located in intracellular compartment. "
"GUCY1B1","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"HABP4","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"HAND1","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","6: Protein located in intracellular compartment. "
"HAVCR2","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"HCK","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"HCLS1","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"HCP5","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","No value","No value","No value","No value"
"HDAC1","1","2018","Harvard-MIT","","AMP-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","6: Protein located in intracellular compartment. "
"HDAC9","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"HEBP2","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"HECW2","1","2019","Chang Lab","Mayo","Community","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"HGF","1","2023","Emory","syn20933797, syn52525880","AMP-AD","Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","1: Secreted protein. Highly accessible to antibody-based therapies."
"HLA-DMB","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","No value","No value","No value","No value"
"HLA-DOA","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","No value","No value","No value","No value"
"HLA-DQB1","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","No value","No value","No value","No value"
"HLA-DRB1","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","No value","No value","No value","No value"
"HNF1A","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"HNRNPA2B1","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","6: Probably small molecule druggable by homology: >=40% homologous to a  protein with a small molecule ligand identified from ChEMBL data, but the ligand does not meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"HNRNPU","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"HPR","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"HS3ST4","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tdark","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"HS3ST5","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"HSDL1","1","2023","Emory","https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2","AMP-AD","Genetics, Protein","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"HSPA2","1","2019","Chang Lab","Kronos, MSBB, Rush","Community","Genetics, Protein, RNA","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"HSPB2","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"HTRA3","1","2023","MSSM - Roussos Lab","FreshMicro","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"IARS1","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ICA1","1","2019","Chang Lab","Mayo, ROSMAP","Community","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ICA1L","1","2020","Emory","Banner, ROSMAP","AMP-AD","Genetics, Protein","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"ICAM1","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","1: Secreted protein. Highly accessible to antibody-based therapies."
"IDH2","1","2019","Chang Lab","Kronos, Mayo, ROSMAP","Community","Genetics, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"IFI30","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"IFIH1","1","2022","Emory-Sage-SGC","","TREAT-AD","Pathway Modeling, Risk Scores","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"IFITM2","1","2019","Chang Lab","Mayo, ROSMAP","Community","Genetics, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"IFNLR1","1","2023","MSSM - Roussos Lab","FreshMicro","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","1: Secreted protein. Highly accessible to antibody-based therapies."
"IGF1R","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"IGFBP5","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","1: Secreted protein. Highly accessible to antibody-based therapies."
"IKBKB","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"IL10","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"IL15","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"IL23R","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"IL6ST","1","2019","Chang Lab","ROSMAP","Community","Genetics, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","1: Secreted protein. Highly accessible to antibody-based therapies."
"IMMT","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"INPPL1","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"INSR","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"IQGAP1","1","2019","Chang Lab","ROSMAP","Community","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"IQUB","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tdark","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"IRS1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"ISYNA1","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"ITGB1","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"ITGB4","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ITGB5","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ITIH2","1","2018","Mayo-UFL-ISB","APP Mice","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"ITPK1","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","No value","No value","No value","No value"
"ITPKB","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"ITPR1","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ITPR2","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"JARID2","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"JMJD6","1","2019","Chang Lab","Mayo, ROSMAP","Community","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"KANK2","1","2023","Mayo-UFL-ISB","Mayo, MC-BrAD, TAUAPPms","AMP-AD","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"KAT2B","1","2019","Chang Lab","ROSMAP","Community","Genetics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"KCNC2","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"KCND3","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"KCNIP1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"KCNJ3","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"KCNK4","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"KCNN2","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"KCNN3","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"KCNN4","1","2023","MSSM - Roussos Lab","FreshMicro","AMP-AD","Genetics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"KCNQ5","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"KDM3B","1","2019","Chang Lab","Kronos, Mayo, ROSMAP, Rush","Community","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"KHDRBS2","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"KIAA1549L","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tdark","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"KIDINS220","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"KIF13B","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"KLC1-AS1","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","No value","No value","No value","No value"
"KLF15","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"KLHDC9","1","2023","Emory","https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2","AMP-AD","Genetics, Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"KLHL29","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"KPNB1","1","2019","Chang Lab","MSBB","Community","Genetics, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"KRT8","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"LAMA4","1","2020","ASU","ROSMAP","AMP-AD","Genetics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","1: Secreted protein. Highly accessible to antibody-based therapies."
"LAMB2","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","1: Secreted protein. Highly accessible to antibody-based therapies."
"LAMP5","1","2023","MSSM - Roussos Lab","FreshMicro","AMP-AD","RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"LDB2","1","2019","Chang Lab","Kronos, Mayo, ROSMAP","Community","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"LDB3","1","2023","Mayo-UFL-ISB","GSE197305, Mayo, MC-CAA, ROSMAP","AMP-AD","Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"LGALS9","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"LILRA2","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","No value","No value","No value","No value"
"LILRB1","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","No value","No value","No value","No value"
"LIMS1","1","2020","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"LINGO2","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"LIPC","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"LMO7","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"LMOD3","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"LNX1","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","1: Secreted protein. Highly accessible to antibody-based therapies."
"LPAR6","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"LPCAT3","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tbio","9: Potentially small molecule druggable by family (active ligand): is a member of a gene family which has a member with an small molecule ligand identified from ChEMBL data, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"LPIN1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"LPP","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"LRAT","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","1: Secreted protein. Highly accessible to antibody-based therapies."
"LRP1","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"LRPPRC","1","2019","Chang Lab","MSBB","Community","Genetics, Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"LRRC25","1","2023","MSSM - Roussos Lab","FreshMicro","AMP-AD","Genetics, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"LRRC8D","1","2020","ASU","ROSMAP","AMP-AD","Genetics, Protein, RNA","Tdark","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"LY86","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"LYL1","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"LYN","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","Genetics, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"MAF1","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"MAML3","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","6: Protein located in intracellular compartment. "
"MANF","1","2020","ASU","ROSMAP","AMP-AD","Genetics, Protein, RNA","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"MAOB","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"MAP1B","1","2019","Chang Lab","Kronos, Mayo, MSBB, ROSMAP, Rush","Community","Genetics, Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"MAP2","1","2019","Chang Lab","Kronos, MSBB, ROSMAP, Rush","Community","Genetics, Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"MAP4","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"MAP7","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"MAPK1","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"MAPK9","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"MARK4","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"MBD3","1","2018","Mayo-UFL-ISB","APP Mice","AMP-AD","Protein","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"MBP","1","2023","Mayo-UFL-ISB","GSE197305, Mayo, MC-CAA, ROSMAP","AMP-AD","Protein, RNA","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"MDH1","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"MDH2","1","2019","Chang Lab","Kronos, Mayo, MSBB, Rush","Community","Genetics, Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"MFF","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"MFNG","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"MGST3","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"MITF","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"MKNK1","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"MMP17","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"MNDA","1","2023","MSSM - Roussos Lab","FreshMicro","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"MOG","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","No value","No value","No value","No value"
"MRPL1","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"MRPL11","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"MRPL12","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"MRPL14","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tdark","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"MRPL15","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"MRPL16","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tdark","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"MRPL17","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"MRPL30","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"MRPL39","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tdark","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"MRPL40","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"MRPL43","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"MRPL44","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"MRPL46","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tdark","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"MRPL48","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tdark","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"MRPL49","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"MRPL50","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"MRPL53","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"MRPL57","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","6: Protein located in intracellular compartment. "
"MRPL58","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"MRPS15","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"MRPS16","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"MRPS18B","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"MRPS2","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tdark","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"MRPS22","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"MRPS23","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tdark","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"MS4A2","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","10: Potentially small molecule druggable by family (low activity ligand): is a member of a gene family which has a protein member with a ligand which does not meet TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"MS4A7","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tdark","10: Potentially small molecule druggable by family (low activity ligand): is a member of a gene family which has a protein member with a ligand which does not meet TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"MT1G","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"MTHFD1","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"MTMR10","1","2019","Chang Lab","Kronos, ROSMAP","Community","Genetics, RNA","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"MTSS2","1","2023","Emory","https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2","AMP-AD","Genetics, Protein","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","6: Protein located in intracellular compartment. "
"MYO1D","1","2019","Chang Lab","Kronos, MSBB","Community","Genetics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"MYO1E","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"MYO1F","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"MYRF","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"N4BP3","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tdark","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"NBAS","1","2020","ASU","ROSMAP","AMP-AD","Genetics, Protein, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"NCKAP1L","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"NCKAP5","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ND3","1","2020","ASU","ROSMAP","AMP-AD","Genetics, Protein, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"NDUFA11","1","2019","Chang Lab","MSBB","Community","Genetics, Protein","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"NDUFA13","1","2019","Chang Lab","Mayo, MSBB, ROSMAP","Community","Genetics, Protein, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"NDUFA9","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"NDUFS6","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"NDUFS7","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"NECTIN2","1","2020","Duke BARU","Cardiovascular Health Study, Framingham Heart Study, Health and Retirement Study, Late Onset Alzheimer's Disease Family Study","Community","Genetics","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"NEDD9","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"NEFL","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"NEUROD6","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"NFKBIA","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"NFKBIZ","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","6: Protein located in intracellular compartment. "
"NFS1","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"NGFR","1","2021","Longo Lab","AD Mouse Models, MSBB, ROSMAP","Community","Genetics, Protein, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"NHSL1","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","6: Protein located in intracellular compartment. "
"NIPSNAP2","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"NKAIN2","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"NLK","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"NMNAT2","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"NPC1","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"NPM3","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"NR1H2","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"NR1H3","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"NR1H4","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"NR3C1","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"NR5A2","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"NRG1","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"NSF","1","2019","Chang Lab","Kronos, Mayo, MSBB, ROSMAP, Rush","Community","Genetics, Protein, RNA","No value","No value","No value","No value"
"NTN1","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"NTN3","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"NTRK2","1","2023","Longo Lab","https://doi.org/10.1002/ajmg.b.30607, https://doi.org/10.1016/j.celrep.2020.107908, https://doi.org/10.1016/j.nbd.2019.104540, https://doi.org/10.1016/j.neulet.2013.06.061, https://doi.org/10.1038/tp.2015.55, https://doi.org/10.3233/jad-2008-15105","Community","Genetics, Phenomics, Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"NUAK2","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"NUMA1","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"NUPR1","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"NXPH1","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"NXPH2","1","2023","Emory","syn20933797, syn52525880","AMP-AD","Protein","Tdark","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"NYAP1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tdark","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"OLFML3","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tdark","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"OPALIN","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tdark","13: Unknown: There is no information on ligands or structure in any of the categories above. ","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"OR2B2","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tdark","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"OSBPL3","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"OXR1","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"P2RY12","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"P2RY13","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PACSIN1","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"PALLD","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"PAPOLA","1","2019","Chang Lab","Mayo, ROSMAP, Rush","Community","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PAQR9","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PARP8","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","6: Protein located in intracellular compartment. "
"PARP9","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"PAX6","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PCDHA6","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tdark","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","1: Secreted protein. Highly accessible to antibody-based therapies."
"PCED1B","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tdark","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"PCLO","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PCM1","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"PCSK9","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"PDCD1","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","No value","No value","No value","No value"
"PDE10A","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"PDE1A","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"PFKP","1","2019","Chang Lab","MSBB, ROSMAP","Community","Genetics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"PGM2L1","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"PGM5","1","2020","ASU","ROSMAP","AMP-AD","Genetics, Protein, RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"PHF24","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"PHGDH","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PHYHD1","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tdark","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","6: Protein located in intracellular compartment. "
"PIK3AP1","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"PIK3CA","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"PIK3CB","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"PKD2L1","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PLAT","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"PLCD1","1","2020","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"PLD4","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PLEK","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"PLEKHA1","1","2020","Emory","Banner, ROSMAP","AMP-AD","Genetics, Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"PLEKHG1","1","2023","MSSM - Roussos Lab","FreshMicro","AMP-AD","RNA","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"PLEKHH1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PLG","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"PLIN4","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"PLLP","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PLP1","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PLPP4","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PLPPR4","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PLXDC2","1","2023","Emory","https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2","AMP-AD","Genetics, Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PLXNA1","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PNMA2","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"PNPLA3","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"POLR2G","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"PPARA","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","6: Protein located in intracellular compartment. "
"PPARG","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","6: Protein located in intracellular compartment. "
"PPP1CC","1","2019","Chang Lab","Mayo, ROSMAP","Community","Genetics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PPP1R18","1","2019","Chang Lab","Mayo, ROSMAP","Community","Genetics, RNA","No value","No value","No value","No value"
"PPP1R7","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"PPP3CA","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PREPL","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"PRKAR2B","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"PRKCA","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PRPF31","1","2020","ASU","ROSMAP","AMP-AD","Genetics, Protein, RNA","No value","No value","No value","No value"
"PSAP","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"PSAT1","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"PSME1","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"PSPH","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"PTK2B","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","Genetics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"PTPRG","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PTPRR","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PTPRZ1","1","2019","Chang Lab","ROSMAP","Community","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"PTTG1IP","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"PYGL","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"QKI","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"QPCT","1","2023","Emory","https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2","AMP-AD","Genetics, Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","1: Secreted protein. Highly accessible to antibody-based therapies."
"QPRT","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","1: Secreted protein. Highly accessible to antibody-based therapies."
"RAB21","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"RAB3IL1","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"RABEP2","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tdark","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"RANBP2","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"RAPGEF2","1","2020","ASU","ROSMAP","AMP-AD","Genetics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"RAPSN","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"RDX","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"RENBP","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"REST","1","2018","Harvard-MIT","","AMP-AD","RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"RET","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"RGPD5","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"RHBDF2","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"RHPN2","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"RIMS2","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"RIN3","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"RNASE6","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"ROBO1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"RPS6KA2","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"RRBP1","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"RREB1","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"RRM1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"RRM2B","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"RSPO2","1","2023","Emory","syn20933797, syn52525880","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"RTN1","1","2019","Chang Lab","Kronos, Mayo, MSBB, ROSMAP, Rush","Community","Genetics, Protein, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"RTN3","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"RTN4","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"RXRA","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"S100A11","1","2020","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"S100A4","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","6: Probably small molecule druggable by homology: >=40% homologous to a  protein with a small molecule ligand identified from ChEMBL data, but the ligand does not meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"S100A6","1","2019","Chang Lab","MSBB","Community","Genetics, Protein","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"S100A8","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"S100A9","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"S1PR1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SAMD4A","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"SASH1","1","2019","Chang Lab","Kronos, Mayo, ROSMAP","Community","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"SCG3","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"SCML4","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"SCN2A","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SCN7A","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SCN8A","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SCN9A","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SCRN2","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tdark","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"SDHA","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"SDR42E1","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SDR9C7","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"SELENBP1","1","2023","MSSM - Roussos Lab","FreshMicro","AMP-AD","RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"SEMA3F","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"SENP1","1","2019","Chang Lab","ROSMAP","Community","Genetics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"SEPTIN10","1","2019","Chang Lab","Mayo, MSBB","Community","Genetics, Protein, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"SEPTIN11","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"SERPINA1","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","No value","No value","No value","No value"
"SERPINA3","1","2018","Mayo-UFL-ISB","APP Mice","AMP-AD","Protein","Tbio","6: Probably small molecule druggable by homology: >=40% homologous to a  protein with a small molecule ligand identified from ChEMBL data, but the ligand does not meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"SERPINI1","1","2020","ASU","ROSMAP","AMP-AD","Genetics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"SGIP1","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"SGK1","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SGPL1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SGPP1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SH3GLB2","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"SIDT2","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"SIGLEC1","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SIGLEC14","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SIGLEC8","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SIGLEC9","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLA","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"SLC12A4","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLC16A9","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLC1A2","1","2019","Chang Lab","Kronos, Mayo, ROSMAP, Rush","Community","Genetics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLC1A5","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLC22A23","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLC22A4","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLC24A4","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLC25A19","1","2020","ASU","ROSMAP","AMP-AD","Genetics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLC25A4","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","6: Probably small molecule druggable by homology: >=40% homologous to a  protein with a small molecule ligand identified from ChEMBL data, but the ligand does not meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLC25A45","1","2019","Chang Lab","Mayo, ROSMAP","Community","Genetics, RNA","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLC2A5","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"SLC2A8","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLC30A3","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLC35C1","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLC38A2","1","2019","Chang Lab","Mayo, ROSMAP, Rush","Community","Genetics, RNA","Tbio","6: Probably small molecule druggable by homology: >=40% homologous to a  protein with a small molecule ligand identified from ChEMBL data, but the ligand does not meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLC4A10","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLC5A3","1","2019","Chang Lab","Mayo, ROSMAP","Community","Genetics, RNA","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLC7A7","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLC8A2","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLC9A7","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLCO1A2","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","1: Secreted protein. Highly accessible to antibody-based therapies."
"SLCO2B1","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLIT1","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"SLITRK4","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SLMAP","1","2023","Emory","syn20933797, syn52525880","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SMAD3","1","2023","Mayo","MC_snRNA","Resilience-AD","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SMAD4","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"SMARCA5","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"SMC3","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"SMOC2","1","2023","Emory","syn20933797, syn52525880","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"SNAP25","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SNCA","1","2019","Chang Lab","Mayo, Rush","Community","Genetics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"SNTB1","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"SNX27","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"SP1","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"SP6","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"SPATA22","1","2020","ASU","ROSMAP","AMP-AD","Genetics, Protein, RNA","Tdark","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"SPATS1","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"SPCS1","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tdark","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SPG7","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"SPI1","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SPOCK1","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"SPOCK2","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"SPOCK3","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"SPTB","1","2020","ASU","ROSMAP","AMP-AD","Genetics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"SPTLC1","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SPTLC3","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SREBF1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SREBF2","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SRR","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SRSF2","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"ST18","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","9: Potentially small molecule druggable by family (active ligand): is a member of a gene family which has a member with an small molecule ligand identified from ChEMBL data, meeting TCRD activity criteria.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"ST8SIA3","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"STARD10","1","2019","Chang Lab","ROSMAP","Community","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"STAU1","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"STK10","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"STOM","1","2023","Mayo-UFL-ISB","Mayo, MC-BrAD, TAUAPPms","AMP-AD","Genetics, RNA","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"STX1B","1","2023","Emory","https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2","AMP-AD","Genetics, Protein","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"STXBP1","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"STXBP3","1","2023","Emory","https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2","AMP-AD","Genetics, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"STXBP5L","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SULT1A3","1","2020","ASU","ROSMAP","AMP-AD","Genetics, Protein, RNA","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"SULT2A1","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"SULT4A1","1","2019","Chang Lab","Kronos, Mayo, ROSMAP","Community","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"SUMF1","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"SYN1","1","2019","Chang Lab","Kronos, Mayo, MSBB, ROSMAP, Rush","Community","Genetics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"SYN2","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"SYNGR4","1","2020","ASU","ROSMAP","AMP-AD","Genetics, Protein, RNA","Tdark","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SYNJ1","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SYNPO","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"SYP","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SYT12","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"SYT13","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TAL1","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"TARDBP","1","2020","ASU","ROSMAP","AMP-AD","Genetics, Protein, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"TBXAS1","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TESPA1","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"TGFB1","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","1: Secreted protein. Highly accessible to antibody-based therapies."
"TICAM1","1","2022","Emory-Sage-SGC","","TREAT-AD","Pathway Modeling, Risk Scores","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"TIMM13","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"TIMP3","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"TJP2","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TKFC","1","2023","Duke","","AMP-AD","Genetics, Metabolomics, Phenomics, Protein, RNA","Tbio","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TLR1","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"TLR4","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","1: Secreted protein. Highly accessible to antibody-based therapies."
"TLR5","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TLR7","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TM6SF2","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TMBIM1","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TMEFF2","1","2020","Emory","Banner, Emory, MSBB, ROSMAP","AMP-AD","Protein","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TMEM119","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"TMEM184B","1","2019","Chang Lab","Mayo, ROSMAP","Community","Genetics, RNA","Tdark","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TMEM229B","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tdark","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TMEM258","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tdark","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TMPO","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","No value","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TMX3","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"TNFAIP8","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"TNFRSF11B","1","2023","MSSM - Roussos Lab","FreshMicro","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"TNS1","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"TOMM70","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TPR","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"TPST1","1","2019","Chang Lab","Kronos, Mayo, ROSMAP, Rush","Community","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"TREML1","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TRHDE","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TRIOBP","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Genetics, Protein, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"TRPC3","1","2021","JAX-VUMC-UW Resilience","AD-BXD mice","Resilience-AD","Genetics, Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TRPM1","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TSPAN7","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TTBK2","1","2020","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TTYH2","1","2019","Chang Lab","Kronos, Mayo, ROSMAP, Rush","Community","Genetics, RNA","Tdark","11: Druggable protein class, no other information: Is a member of a PHAROS druggable class of protein (enzyme, receptor, ion channel, nuclear hormone receptor, kinase) but does not meet any of the criteria above.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TUBB3","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"TUFM","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"UBE2T","1","2019","Chang Lab","ROSMAP","Community","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"UGT8","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"UNC119B","1","2019","Chang Lab","Mayo","Community","Genetics, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"UNC13A","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"UNC5C","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","4: Targetable by homologous structure: >=40% homologous to a structurally druggable protein, based on the presence of a druggable pocket in the homologous protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"UNC79","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","No value","No value","No value","No value"
"UQCRB","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"UQCRC1","1","2018","Columbia-Rush","ROSMAP","AMP-AD","Clinical, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"UQCRC2","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"UQCRFS1","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"USP50","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"USP6NL","1","2023","MSSM - Roussos Lab","FreshMicro","AMP-AD","Genetics, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"UTRN","1","2023","MSSM - Zhang Lab","MSBB","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"VAV1","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","Genetics, RNA","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"VCAN","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"VCP","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"VEGFA","1","2023","Mayo","MC_snRNA","Resilience-AD","Genetics, RNA","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"VIM","1","2020","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"VKORC1","1","2023","Emory","https://doi.org/10.1038/s41588-018-0311-9; https://doi.org/10.1038/s41588-019-0358-2","AMP-AD","Genetics, Protein","Tclin","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","1: Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.","1: Secreted protein. Highly accessible to antibody-based therapies."
"VSIG4","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"VTN","1","2018","Mayo-UFL-ISB","APP Mice","AMP-AD","Protein","Tbio","3: Targetable by structure: Structurally druggable protein, based on the presence of a druggable pocket in the protein (DrugEBIlity/CanSAR).","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"WAS","1","2022","IUSM-Purdue","ABA, GSE33000, GSE44772, GSE48350, GSE5281, Mayo, MSBB, ROSMAP","TREAT-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"WDR7","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","4: Limited evidence that target is a secreted protein, ECM component or cell membrane-bound protein. "
"WLS","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"WNT10B","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","9: Potentially small molecule druggable by family (active ligand): is a member of a gene family which has a member with an small molecule ligand identified from ChEMBL data, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"WNT2B","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tbio","9: Potentially small molecule druggable by family (active ligand): is a member of a gene family which has a member with an small molecule ligand identified from ChEMBL data, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"WNT7B","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tbio","2: Targetable by homology: >=40% homologous to a protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","1: Secreted protein. Highly accessible to antibody-based therapies."
"YAP1","1","2018","MSSM - Zhang Lab","MSBB","AMP-AD","Genetics, RNA","Tbio","12: Potentially low ligandability: Has a structure but there is no evidence of a druggable pocket.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"YARS1","1","2018","Emory","ACT, Banner, BLSA","AMP-AD","Protein","Tchem","1: Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.","5: Clinical data with evidence of intolerable safety profile/adverse drug reactions in the desired modality and with target engagement. Drug for target withdrawn on those grounds.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"YIF1B","1","2019","Chang Lab","ROSMAP","Community","Genetics, RNA","Tbio","13: Unknown: There is no information on ligands or structure in any of the categories above. ","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ZBTB16","1","2018","Mayo-UFL-ISB","Mayo","AMP-AD","RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","7: Dark target. Paucity of biological knowledge means progress will be difficult. Encourage others to investigate. "
"ZFP3","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","5: Protein located in the cytosol. Not practically accessible to antibody-based therapies, but may be more easily accessible to other modalities."
"ZNF225","1","2023","ASU","VirusResilience","AMP-AD","RNA","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"ZNF536","1","2018","Duke","ADNI","AMP-AD","Genetics, Metabolomics","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"ZNF618","1","2023","MSSM - Roussos Lab","HBI_scRNAseq","AMP-AD","RNA","Tdark","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","2: No major issues found from gene expression, genetic or pharmacological profiling, but has not been extensively tested in humans.","3: Cell membrane-bound proteins. Highly accessible to antibody-based therapies, but potentially less so than secreted proteins or ECM components."
"ZNF652","1","2023","MSSM - Roussos Lab","FreshMicro","AMP-AD","Genetics, RNA","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","3: Two or fewer of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"ZPR1","1","2023","Duke","ADNI, AIBL","AMP-AD","Genetics, Metabolomics","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "
"ZWINT","1","2018","Mayo-UFL-ISB","APP Mice","AMP-AD","Protein","Tbio","7: Potentially targetable by protein family structure:  is a member of a gene family which has a protein member with a druggable pocket in the protein structure.","4: More than two of: high off target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.","6: Protein located in intracellular compartment. "